Identification and Clinical Characteristics of Community-Acquired in Patients Hospitalized for Moderate or Severe COVID-19 in Peru.

Wilmer Silva-Caso, Giancarlo Pérez-Lazo, Miguel Angel Aguilar-Luis, Adriana Morales-Moreno, José Ballena-López, Fernando Soto-Febres, Johanna Martins-Luna, Luis J Del Valle, Sungmin Kym, Deysi Aguilar-Luis, Dayana Denegri-Hinostroza, Juana Del Valle-Mendoza
Author Information
  1. Wilmer Silva-Caso: School of Medicine, Research Center of the Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru. ORCID
  2. Giancarlo Pérez-Lazo: Division of Infectious Diseases, Guillermo Almenara Irigoyen National Hospital-EsSalud, Lima 15033, Peru. ORCID
  3. Miguel Angel Aguilar-Luis: School of Medicine, Research Center of the Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru. ORCID
  4. Adriana Morales-Moreno: Division of Infectious Diseases, Guillermo Almenara Irigoyen National Hospital-EsSalud, Lima 15033, Peru.
  5. José Ballena-López: Division of Infectious Diseases, Guillermo Almenara Irigoyen National Hospital-EsSalud, Lima 15033, Peru.
  6. Fernando Soto-Febres: Division of Infectious Diseases, Guillermo Almenara Irigoyen National Hospital-EsSalud, Lima 15033, Peru.
  7. Johanna Martins-Luna: School of Medicine, Research Center of the Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.
  8. Luis J Del Valle: Barcelona Research Center for Multiscale Science and Engineering, Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya (UPC), 08034 Barcelona, Spain. ORCID
  9. Sungmin Kym: Korea International Cooperation for Infectious Diseases, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
  10. Deysi Aguilar-Luis: School of Medicine, Research Center of the Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.
  11. Dayana Denegri-Hinostroza: School of Medicine, Research Center of the Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.
  12. Juana Del Valle-Mendoza: School of Medicine, Research Center of the Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.

Abstract

has been described as a cause of serious community-acquired infections in tropical countries. Currently, its implications when simultaneously identified with other pathogens are not yet adequately understood. A descriptive study was conducted on hospitalized patients with a diagnosis of moderate/severe SARS-CoV-2-induced pneumonia confirmed via real-time RT-PCR. Patients aged > 18 years who were admitted to a specialized COVID-19 treatment center in Peru were selected for enrollment. was detected via the PCR amplification of the gene obtained from nasopharyngeal swabs within 48 h of hospitalization. A total of 295 patients with COVID-19 who met the study inclusion criteria were enrolled. was simultaneously identified in 40/295 (13.5%) of COVID-19-hospitalized patients. Demographic data and comorbidities were comparable in both -positive and -negative subgroups. However, patients identified as being infected with were more likely to have received outpatient antibiotics prior to hospitalization, had a higher requirement for high-flow nasal cannula and a higher subjective incidence of fatigue, and were more likely to develop -induced pneumonia during hospitalization. Conclusions: The group in which SARS-CoV-2 and were simultaneously identified had a higher proportion of fatigue, a higher frequency of requiring a high-flow cannula, and a higher proportion of superinfection with the same microorganism during hospitalization.

Keywords

References

  1. Medicine (Madr). 2022 May;13(55):3224-3234 [PMID: 35582693]
  2. Infect Chemother. 2016 Sep;48(3):174-180 [PMID: 27659440]
  3. Clin Microbiol Rev. 2008 Jul;21(3):538-82 [PMID: 18625687]
  4. Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55 [PMID: 24329732]
  5. Microorganisms. 2022 Mar 28;10(4): [PMID: 35456774]
  6. JAMA. 2020 May 26;323(20):2085-2086 [PMID: 32293646]
  7. BMC Infect Dis. 2020 Jan 15;20(1):45 [PMID: 31941459]
  8. JAMA. 2012 Jun 20;307(23):2526-33 [PMID: 22797452]
  9. IUBMB Life. 2020 Oct;72(10):2097-2111 [PMID: 32770825]
  10. Pneumonia (Nathan). 2021 Apr 25;13(1):5 [PMID: 33894790]
  11. Open Forum Infect Dis. 2021 May 05;8(6):ofab201 [PMID: 34099978]
  12. J Pers Med. 2022 Aug 07;12(8): [PMID: 36013244]
  13. N Engl J Med. 2015 Jul 30;373(5):415-27 [PMID: 26172429]
  14. Semin Respir Crit Care Med. 2020 Aug;41(4):480-495 [PMID: 32629487]
  15. J Biomed Inform. 2020 Sep;109:103540 [PMID: 32814200]
  16. Trop Med Infect Dis. 2023 Aug 18;8(8): [PMID: 37624357]
  17. Intern Med. 2019 Jan 15;58(2):301-305 [PMID: 30210104]
  18. Rev Soc Bras Med Trop. 2022 Nov 21;55:e03012022 [PMID: 36417622]
  19. Antibiotics (Basel). 2021 Nov 07;10(11): [PMID: 34827296]
  20. BMC Pulm Med. 2023 Apr 26;23(1):146 [PMID: 37101265]
  21. Infect Drug Resist. 2019 Jun 06;12:1545-1553 [PMID: 31239730]
  22. Clin Microbiol Infect. 2011 Nov;17 Suppl 6:E1-59 [PMID: 21951385]
  23. Pathog Dis. 2014 Aug;71(3):292-301 [PMID: 24376225]
  24. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67 [PMID: 31573350]
  25. BMC Res Notes. 2021 Nov 10;14(1):412 [PMID: 34758882]
  26. Respirology. 2009 Nov;14(8):1200-5 [PMID: 19909464]
  27. Curr Opin Pulm Med. 2020 May;26(3):241-248 [PMID: 32068574]
  28. Clin Microbiol Rev. 2017 Jan;30(1):409-447 [PMID: 27974412]
  29. Tohoku J Exp Med. 2020;250(4):271-278 [PMID: 32321874]
  30. Antimicrob Agents Chemother. 2010 Nov;54(11):4575-81 [PMID: 20713680]
  31. Expert Rev Anti Infect Ther. 2015 May;13(5):567-73 [PMID: 25850806]
  32. Int J Hyg Environ Health. 2022 Jul;244:114006 [PMID: 35841823]
  33. PLoS One. 2010 Nov 30;5(11):e14133 [PMID: 21152436]
  34. Infect Dis Clin North Am. 2016 Dec;30(4):967-997 [PMID: 27660090]
  35. Ann Intern Med. 2022 Apr;175(4):ITC49-ITC64 [PMID: 35404672]
  36. PLoS One. 2022 Apr 15;17(4):e0267184 [PMID: 35427402]
  37. Microb Pathog. 2022 Apr;165:105506 [PMID: 35358660]

Grants

  1. EXP-09 - 2018 - UPC/Peruvian University of Applied Sciences
  2. 2016M3A9B8942289/Bio & Medical Technology Development Program of the National Research Foundation (NRF)

Word Cloud

Created with Highcharts 10.0.0higheridentifiedpatientshospitalizationsimultaneouslyCOVID-19community-acquiredinfectionsstudypneumoniaviaPatientsPerugenelikelyhigh-flowcannulafatigueproportiondescribedcauseserioustropicalcountriesCurrentlyimplicationspathogensyetadequatelyunderstooddescriptiveconductedhospitalizeddiagnosismoderate/severeSARS-CoV-2-inducedconfirmedreal-timeRT-PCRaged>18yearsadmittedspecializedtreatmentcenterselectedenrollmentdetectedPCRamplificationobtainednasopharyngealswabswithin48htotal295metinclusioncriteriaenrolled40/295135%COVID-19-hospitalizedDemographicdatacomorbiditiescomparable-positive-negativesubgroupsHoweverinfectedreceivedoutpatientantibioticspriorrequirementnasalsubjectiveincidencedevelop-inducedConclusions:groupSARS-CoV-2frequencyrequiringsuperinfectionmicroorganismIdentificationClinicalCharacteristicsCommunity-AcquiredHospitalizedModerateSevereAcinetobacterbaumanniiOXA-51

Similar Articles

Cited By